Daniel C Javitt

List of Publications by Year
in descending order

118 papers	11,871 citations	30070 54 h-index	28297 105 g-index
120 all docs	120 docs citations	120 times ranked	9812 citing authors

#	Article	IF	Citations
1	Computational modeling of excitatory/inhibitory balance impairments in schizophrenia. Schizophrenia Research, 2022, 249, 47-55.	2.0	7
2	Mismatch negativity as an index of target engagement for excitation/inhibition-based treatment development: a double-blind, placebo-controlled, randomized, single-dose cross-over study of the serotonin type-3 receptor antagonist CVN058. Neuropsychopharmacology, 2022, 47, 711-718.	5.4	10
3	Relationships between Diffusion Tensor Imaging and Resting State Functional Connectivity in Patients with Schizophrenia and Healthy Controls: A Preliminary Study. Brain Sciences, 2022, 12, 156.	2.3	3
4	The glutamate/N-methyl-d-aspartate receptor (NMDAR) model of schizophrenia at 35: On the path from syndrome to disease. Schizophrenia Research, 2022, 242, 56-61.	2.0	12
5	Efficacy of Transcranial Direct Current Stimulation to Improve Insight in Patients With Schizophrenia: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Schizophrenia Bulletin, 2022, 48, 1284-1294.	4.3	5
6	What you see is what you get: visual scanning failures of naturalistic social scenes in schizophrenia. Psychological Medicine, 2021, 51, 2923-2932.	4.5	11
7	Neurophysiological, Oculomotor, and Computational Modeling of Impaired Reading Ability in Schizophrenia. Schizophrenia Bulletin, 2021, 47, 97-107.	4.3	11
8	Failure to engage the temporoparietal junction/posterior superior temporal sulcus predicts impaired naturalistic social cognition in schizophrenia. Brain, 2021, 144, 1898-1910.	7.6	14
9	Ventromedial prefrontal cortex/anterior cingulate cortex Glx, glutamate, and GABA levels in medication-free major depressive disorder. Translational Psychiatry, 2021, 11, 419.	4.8	45
10	Translational Mechanistic Biomarkers for the 21st Century. American Journal of Psychiatry, 2021, 178, 893-895.	7.2	1
11	The Thalamocortical Circuit of Auditory Mismatch Negativity. Biological Psychiatry, 2020, 87, 770-780.	1.3	58
12	The characteristics of cognitive neuroscience tests in a schizophrenia cognition clinical trial: Psychometric properties and correlations with standard measures. Schizophrenia Research: Cognition, 2020, 19, 100161.	1.3	2
13	Translational neurophysiological biomarkers of N-methyl-d-aspartate receptor dysfunction in serine racemase knockout mice. Biomarkers in Neuropsychiatry, 2020, 2, 100019.	1.0	8
14	Deficits and compensation: Attentional control cortical networks in schizophrenia. NeuroImage: Clinical, 2020, 27, 102348.	2.7	17
15	A roadmap for development of neuro-oscillations as translational biomarkers for treatment development in neuropsychopharmacology. Neuropsychopharmacology, 2020, 45, 1411-1422.	5.4	51
16	Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers. Neuropsychopharmacology, 2020, 45, 1842-1850.	5.4	32
17	Double blind, two dose, randomized, placebo-controlled, cross-over clinical trial of the positive allosteric modulator at the alpha7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patients. Neuropsychopharmacology, 2020, 45, 1339-1345.	5.4	30
18	Impaired Fixation-Related Theta Modulation Predicts Reduced Visual Span and Guided Search Deficits in Schizophrenia. Cerebral Cortex, 2020, 30, 2823-2833.	2.9	6

#	Article	IF	Citations
19	Deficits in Pre-attentive Processing of Spatial Location and Negative Symptoms in Subjects at Clinical High Risk for Schizophrenia. Frontiers in Psychiatry, 2020, 11, 629144.	2.6	10
20	The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: A critical and comprehensive review. Journal of Psychiatric Research, 2019, 108, 57-83.	3.1	54
21	Neural and functional correlates of impaired reading ability in schizophrenia. Scientific Reports, 2019, 9, 16022.	3.3	15
22	Bimodal distribution of tone-matching deficits indicates discrete pathophysiological entities within the syndrome of schizophrenia. Translational Psychiatry, 2019, 9, 221.	4.8	28
23	Differential Patterns of Visual Sensory Alteration Underlying Face Emotion Recognition Impairment and Motion Perception Deficits in Schizophrenia and Autism Spectrum Disorder. Biological Psychiatry, 2019, 86, 557-567.	1.3	51
24	Are basic auditory processes involved in source-monitoring deficits in patients with schizophrenia?. Schizophrenia Research, 2019, 210, 135-142.	2.0	8
25	A century of sensory processing dysfunction in schizophrenia. European Psychiatry, 2019, 59, 77-79.	0.2	15
26	Targeted Treatment of Individuals With Psychosis Carrying a Copy Number Variant Containing a Genomic Triplication of the Glycine Decarboxylase Gene. Biological Psychiatry, 2019, 86, 523-535.	1.3	32
27	Effects of acute N-acetylcysteine challenge on cortical glutathione and glutamate in schizophrenia: A pilot in vivo proton magnetic resonance spectroscopy study. Psychiatry Research, 2019, 275, 78-85.	3.3	21
28	Significant improvement in treatment resistant auditory verbal hallucinations after 5 days of double-blind, randomized, sham controlled, fronto-temporal, transcranial direct current stimulation (tDCS): A replication/extension study. Brain Stimulation, 2019, 12, 981-991.	1.6	39
29	A multicenter study of ketamine effects on functional connectivity: Large scale network relationships, hubs and symptom mechanisms. NeuroImage: Clinical, 2019, 22, 101739.	2.7	27
30	Hierarchical deficits in auditory information processing in schizophrenia. Schizophrenia Research, 2019, 206, 135-141.	2.0	28
31	Inflammatory biomarkers in psychosis and clinical high risk populations. Schizophrenia Research, 2019, 206, 440-443.	2.0	30
32	Impact of baseline early auditory processing on response to cognitive remediation for schizophrenia. Schizophrenia Research, 2019, 208, 397-405.	2.0	30
33	Sensory and cross-network contributions to response inhibition in patients with schizophrenia. NeuroImage: Clinical, 2018, 18, 31-39.	2.7	34
34	Excitatory Amino Acids in Schizophrenia: Both What You Have, and What You Do With Them. Biological Psychiatry, 2018, 83, 470-472.	1.3	4
35	Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms. Schizophrenia Research, 2018, 191, 70-79.	2.0	88
36	Mismatch negativity (MMN) to spatial deviants and behavioral spatial discrimination ability in the etiology of auditory verbal hallucinations and thought disorder in schizophrenia. Schizophrenia Research, 2018, 191, 140-147.	2.0	29

#	Article	IF	Citations
37	Mismatch negativity as a biomarker of theta band oscillatory dysfunction in schizophrenia. Schizophrenia Research, 2018, 191, 51-60.	2.0	79
38	Meta-analysis of mismatch negativity to simple versus complex deviants in schizophrenia. Schizophrenia Research, 2018, 191, 25-34.	2.0	64
39	Developmental trajectory of mismatch negativity and visual event-related potentials in healthy controls: Implications for neurodevelopmental vs. neurodegenerative models of schizophrenia. Schizophrenia Research, 2018, 191, 101-108.	2.0	17
40	Rodent Mismatch Negativity/theta Neuro-Oscillatory Response as a Translational Neurophysiological Biomarker for N-Methyl-D-Aspartate Receptor-Based New Treatment Development in Schizophrenia. Neuropsychopharmacology, 2018, 43, 571-582.	5.4	44
41	Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders. JAMA Psychiatry, 2018, 75, 11.	11.0	88
42	Mismatch negativity: A simple and useful biomarker of N-methyl-d-aspartate receptor (NMDAR)-type glutamate dysfunction in schizophrenia. Schizophrenia Research, 2018, 191, 1-4.	2.0	26
43	A tale of two sites: Differential impairment of frequency and duration mismatch negativity across a primarily inpatient versus a primarily outpatient site in schizophrenia. Schizophrenia Research, 2018, 191, 10-17.	2.0	32
44	Impaired Motion Processing in Schizophrenia and the Attenuated Psychosis Syndrome: Etiological and Clinical Implications. American Journal of Psychiatry, 2018, 175, 1243-1254.	7.2	35
45	Neurofilament light interaction with GluN1 modulates neurotransmission and schizophrenia-associated behaviors. Translational Psychiatry, 2018, 8, 167.	4.8	37
46	Pupillometer-based neurofeedback cognitive training to improve processing speed and social functioning in individuals at clinical high risk for psychosis.. Psychiatric Rehabilitation Journal, 2017, 40, 33-42.	1.1	43
47	Neurophysiological mechanisms of cortical plasticity impairments in schizophrenia and modulation by the NMDA receptor agonist D-serine. Brain, 2016, 139, 3281-3295.	7.6	84
48	Bitopertin in schizophrenia: glass half full?. Lancet Psychiatry,the, 2016, 3, 1092-1093.	7.4	6
49	Biotypes in Psychosis: Has the RDoC Era Arrived?. American Journal of Psychiatry, 2016, 173, 313-314.	7.2	11
50	Targeting glutamate to treat schizophrenia: lessons from recent clinical studies. Psychopharmacology, 2016, 233, 2425-2428.	3.1	22
51	Differential profiles in auditory social cognition deficits between adults with autism and schizophrenia spectrum disorders: A preliminary analysis. Journal of Psychiatric Research, 2016, 79, 21-27.	3.1	28
52	Loneliness in schizophrenia and its possible correlates. An exploratory study. Psychiatry Research, 2016, 246, 211-217.	3.3	72
53	Computational mapping of brain networks. , 2016, , .		0
54	What can the study of first impressions tell us about attitudinal ambivalence and paranoia in schizophrenia?. Psychiatry Research, 2016, 238, 86-92.	3.3	5

#	Article	IF	Citations
55	Fractal Dimension Analysis of Subcortical Gray Matter Structures in Schizophrenia. PLoS ONE, 2016, 11, e0155415.	2.5	27
56	Automated analysis of free speech predicts psychosis onset in high-risk youths. NPJ Schizophrenia, 2015, 1, 15030.	3.6	453
57	Neural oscillatory deficits in schizophrenia predict behavioral and neurocognitive impairments. Frontiers in Human Neuroscience, 2015, 9, 371.	2.0	32
58	Complementary fMRI and EEG evidence for more efficient neural processing of rhythmic vs. unpredictably timed sounds. Frontiers in Psychology, 2015, 6, 1663.	2.1	10
59	Neural Substrates of Auditory Emotion Recognition Deficits in Schizophrenia. Journal of Neuroscience, 2015, 35, 14909-14921.	3.6	80
60	Contributions of early cortical processing and reading ability to functional status in individuals at clinical high risk for psychosis. Schizophrenia Research, 2015, 164, 1-7.	2.0	46
61	D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial. Lancet Psychiatry,the, 2015, 2, 403-412.	7.4	128
62	Neurophysiological models for new treatment development in schizophrenia: early sensory approaches. Annals of the New York Academy of Sciences, 2015, 1344, 92-104.	3.8	64
63	Auditory dysfunction in schizophrenia: integrating clinical and basic features. Nature Reviews Neuroscience, 2015, 16, 535-550.	10.2	312
64	Implicit emotion perception in schizophrenia. Journal of Psychiatric Research, 2015, 71, 112-119.	3.1	16
65	ReplacingDSMCategorical Analyses With Dimensional Analyses in Psychiatry Research. JAMA Psychiatry, 2015, 72, 1159.	11.0	64
66	Sensory Processing Dysfunction in the Personal Experience and Neuronal Machinery of Schizophrenia. American Journal of Psychiatry, 2015, 172, 17-31.	7.2	306
67	Understanding tDCS effects in schizophrenia: a systematic review of clinical data and an integrated computation modeling analysis. Expert Review of Medical Devices, 2014, 11, 383-394.	2.8	61
68	Reading Deficits in Schizophrenia and Individuals at High Clinical Risk: Relationship to Sensory Function, Course of Illness, and Psychosocial Outcome. American Journal of Psychiatry, 2014, 171, 949-959.	7.2	98
69	Glutamatergic abnormalities in schizophrenia: A review of proton MRS findings. Schizophrenia Research, 2014, 152, 325-332.	2.0	144
70	Auditory tasks for assessment of sensory function and affective prosody in schizophrenia. Comprehensive Psychiatry, 2014, 55, 1862-1874.	3.1	15
71	Immediate affective motivation is not impaired in schizophrenia. Schizophrenia Research, 2014, 159, 157-163.	2.0	13
72	Current and Emergent Treatments for Symptoms and Neurocognitive Impairment in Schizophrenia. Current Treatment Options in Psychiatry, 2014, 1, 107-120.	1.9	15

#	Article	IF	Citations
73	Predictive Suppression of Cortical Excitability and Its Deficit in Schizophrenia. Journal of Neuroscience, 2013, 33, 11692-11702.	3.6	106
74	Impaired magnocellular/dorsal stream activation predicts impaired reading ability in schizophrenia. NeuroImage: Clinical, 2013, 2, 8-16.	2.7	37
75	The Spectrotemporal Filter Mechanism of Auditory Selective Attention. Neuron, 2013, 77, 750-761.	8.1	399
76	Reduction in Tonal Discriminations Predicts Receptive Emotion Processing Deficits in Schizophrenia and Schizoaffective Disorder. Schizophrenia Bulletin, 2013, 39, 86-93.	4.3	59
77	Abnormal task modulation of oscillatory neural activity in schizophrenia. Frontiers in Psychology, 2013, 4, 540.	2.1	33
78	Twenty-five Years of Glutamate in Schizophrenia: Are We There Yet?. Schizophrenia Bulletin, 2012, 38, 911-913.	4.3	98
79	Auditory Emotion Recognition Impairments in Schizophrenia: Relationship to Acoustic Features and Cognition. American Journal of Psychiatry, 2012, 169, 424-432.	7.2	99
80	Consequences of Magnocellular Dysfunction on Processing Attended Information in Schizophrenia. Cerebral Cortex, 2012, 22, 1282-1293.	2.9	84
81	Has an Angel Shown the Way? Etiological and Therapeutic Implications of the PCP/NMDA Model of Schizophrenia. Schizophrenia Bulletin, 2012, 38, 958-966.	4.3	268
82	Differential Relationships of Mismatch Negativity and Visual P1 Deficits to Premorbid Characteristics and Functional Outcome in Schizophrenia. Biological Psychiatry, 2012, 71, 521-529.	1.3	76
83	A Roadmap for the Development and Validation of Event-Related Potential Biomarkers in Schizophrenia Research. Biological Psychiatry, 2011, 70, 28-34.	1.3	163
84	Early Sensory Contributions to Contextual Encoding Deficits in Schizophrenia. Archives of General Psychiatry, 2011, 68, 654.	12.3	122
85	Translating Glutamate: From Pathophysiology to Treatment. Science Translational Medicine, 2011, 3, 102mr2.	12.4	147
86	â€œItâ€™s not what you say, but how you say itâ€• a reciprocal temporo-frontal network for affective prosody. Frontiers in Human Neuroscience, 2010, 4, 19.	2.0	108
87	Getting the Cue: Sensory Contributions to Auditory Emotion Recognition Impairments in Schizophrenia. Schizophrenia Bulletin, 2010, 36, 545-556.	4.3	129
88	The importance of a good night's sleep: An open-label trial of the sodium salt of Î³-hydroxybutyric acid in insomnia associated with schizophrenia. Schizophrenia Research, 2010, 120, 225-226.	2.0	16
89	N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: The final common pathway on the road to schizophrenia?. Brain Research Bulletin, 2010, 83, 108-121.	3.0	340
90	Thinking Glutamatergically: Changing Concepts of Schizophrenia Based Upon Changing Neurochemical Models. Clinical Schizophrenia and Related Psychoses, 2010, 4, 189-200.	1.4	98

#	Article	IF	Citations
91	When Doors of Perception Close: Bottom-up Models of Disrupted Cognition in Schizophrenia. Annual Review of Clinical Psychology, 2009, 5, 249-275.	12.3	441
92	Neurophysiological biomarkers for drug development in schizophrenia. Nature Reviews Drug Discovery, 2008, 7, 68-83.	46.4	283
93	Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends in Neurosciences, 2008, 31, 234-242.	8.6	896
94	Magnocellular Pathway Impairment in Schizophrenia: Evidence from Functional Magnetic Resonance Imaging. Journal of Neuroscience, 2008, 28, 7492-7500.	3.6	183
95	Subcortical visual dysfunction in schizophrenia drives secondary cortical impairments. Brain, 2007, 130, 417-430.	7.6	291
96	Reply: A few remarks on assessing magnocellular sensitivity in patients with schizophrenia. Brain, 2007, 130, e84-e84.	7.6	7
97	The Neural Substrates of Impaired Prosodic Detection in Schizophrenia and Its Sensorial Antecedents. American Journal of Psychiatry, 2007, 164, 474-482.	7.2	122
98	Glutamate and Schizophrenia: Phencyclidine, Nâ€Methylâ€dâ€Aspartate Receptors, and Dopamineâ€“Glutamate Interactions. International Review of Neurobiology, 2007, 78, 69-108.	2.0	463
99	Neurocognitive and symptom correlates of daily problem-solving skills in schizophrenia. Schizophrenia Research, 2006, 83, 237-245.	2.0	88
100	Reading impairment and visual processing deficits in schizophrenia. Schizophrenia Research, 2006, 87, 238-245.	2.0	101
101	Theory of Mind (ToM) and counterfactuality deficits in schizophrenia: misperception or misinterpretation?. Psychological Medicine, 2006, 36, 1075-1083.	4.5	69
102	Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients. Current Opinion in Psychiatry, 2006, 19, 151-157.	6.3	78
103	Early-Stage Visual Processing and Cortical Amplification Deficits in Schizophrenia. Archives of General Psychiatry, 2005, 62, 495.	12.3	325
104	Impairments in generation of early-stage transient visual evoked potentials to magno- and parvocellular-selective stimuli in schizophrenia. Clinical Neurophysiology, 2005, 116, 2204-2215.	1.5	132
105	Sensory Contributions to Impaired Prosodic Processing in Schizophrenia. Biological Psychiatry, 2005, 58, 56-61.	1.3	189
106	Reversal of Phencyclidine-Induced Dopaminergic Dysregulation by N-Methyl-D-Aspartate Receptor/Glycine-site Agonists. Neuropsychopharmacology, 2004, 29, 300-307.	5.4	100
107	Magnocellular and parvocellular contributions to backward masking dysfunction in schizophrenia. Schizophrenia Research, 2003, 64, 91-101.	2.0	121
108	Madness in the garden or worm in the apple?. Trends in Cognitive Sciences, 2002, 6, 187.	7.8	0

#	Article	IF	Citations
109	Glycine modulators in schizophrenia. Current Opinion in Investigational Drugs, 2002, 3, 1067-72.	2.3	27
110	Somatosensory Input to Auditory Association Cortex in the Macaque Monkey. Journal of Neurophysiology, 2001, 85, 1322-1327.	1.8	368
111	Continuous Phencyclidine Treatment Induces Schizophrenia-Like Hyperreactivity of Striatal Dopamine Release. Neuropsychopharmacology, 2001, 25, 157-164.	5.4	52
112	Auditory Sensory Dysfunction in Schizophrenia. Archives of General Psychiatry, 2000, 57, 1149.	12.3	156
113	Deficits in Auditory and Visual Context-Dependent Processing in Schizophrenia. Archives of General Psychiatry, 2000, 57, 1131.	12.3	210
114	Ketamine-Induced Deficits in Auditory and Visual Context-Dependent Processing in Healthy Volunteers. Archives of General Psychiatry, 2000, 57, 1139.	12.3	552
115	Associated deficits in mismatch negativity generation and tone matching in schizophrenia. Clinical Neurophysiology, 2000, 111, 1733-1737.	1.5	255
116	Impaired mismatch negativity (MMN) generation in schizophrenia as a function of stimulus deviance, probability, and interstimulus/interdeviant interval. Electroencephalography and Clinical Neurophysiology - Evoked Potentials, 1998, 108, 143-153.	2.0	197
117	Impaired precision, but normal retention, of auditory sensory ("echoic") memory information in schizophrenia.. Journal of Abnormal Psychology, 1997, 106, 315-324.	1.9	184
118	Demonstration of mismatch negativity in the monkey. Electroencephalography and Clinical Neurophysiology, 1992, 83, 87-90.	0.3	155